362 related articles for article (PubMed ID: 25919487)
41. Comparative preclinical evaluation of
Trencsényi G; Dénes N; Nagy G; Kis A; Vida A; Farkas F; Szabó JP; Kovács T; Berényi E; Garai I; Bai P; Hunyadi J; Kertész I
J Pharm Biomed Anal; 2017 May; 139():54-64. PubMed ID: 28273651
[TBL] [Abstract][Full Text] [Related]
42. Integrin VLA-4 as a PET imaging biomarker of hyper-adhesion in transgenic sickle mice.
Perkins LA; Nyiranshuti L; Little-Ihrig L; Latoche JD; Day KE; Zhu Q; Tavakoli S; Sundd P; Novelli EM; Anderson CJ
Blood Adv; 2020 Sep; 4(17):4102-4112. PubMed ID: 32882004
[TBL] [Abstract][Full Text] [Related]
43. Preclinical Evaluation of
Ganguly T; Bauer N; Davis RA; Foster CC; Harris RE; Hausner SH; Roncali E; Tang SY; Sutcliffe JL
J Nucl Med; 2023 Apr; 64(4):639-644. PubMed ID: 36207137
[TBL] [Abstract][Full Text] [Related]
44. Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
Chakraborty S; Sarma HD; Vimalnath KV; Pillai MR
Nucl Med Biol; 2013 Oct; 40(7):946-54. PubMed ID: 23850487
[TBL] [Abstract][Full Text] [Related]
45. A Systematic Investigation into the Influence of Net Charge on the Biological Distribution of Radiometalated Peptides Using [
Raheem SJ; Salih AK; Garcia MD; Sharpe JC; Toosi BM; Price EW
Bioconjug Chem; 2023 Mar; 34(3):549-561. PubMed ID: 36800496
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of
Bobba KN; Bidkar AP; Meher N; Fong C; Wadhwa A; Dhrona S; Sorlin A; Bidlingmaier S; Shuere B; He J; Wilson DM; Liu B; Seo Y; VanBrocklin HF; Flavell RR
J Nucl Med; 2023 Jul; 64(7):1076-1082. PubMed ID: 37201957
[No Abstract] [Full Text] [Related]
47. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
Persson M; Rasmussen P; Madsen J; Ploug M; Kjaer A
Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362
[TBL] [Abstract][Full Text] [Related]
48. Tumor Targeting via Sialic Acid: [
Tsoukalas C; Geninatti-Crich S; Gaitanis A; Tsotakos T; Paravatou-Petsotas M; Aime S; Jiménez-Juárez R; Anagnostopoulos CD; Djanashvili K; Bouziotis P
Mol Imaging Biol; 2018 Oct; 20(5):798-807. PubMed ID: 29464496
[TBL] [Abstract][Full Text] [Related]
49. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
50. Synthesis and Preclinical Evaluation of a
Wang T; Xu P; Fang J; Li C; Zeng X; Liu J; Meng L; Zhuang R; Zhang X; Su X; Guo Z
Mol Pharm; 2023 Feb; 20(2):1015-1024. PubMed ID: 36562303
[TBL] [Abstract][Full Text] [Related]
51. Molecular Imaging of Very Late Antigen-4 in Acute Lung Injury.
Haddad J; Latoche JD; Nigam S; Bellavia MC; Day KE; Zhu Q; Edwards WB; Anderson CJ; Tavakoli S
J Nucl Med; 2021 Feb; 62(2):280-286. PubMed ID: 32680928
[TBL] [Abstract][Full Text] [Related]
52. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
[TBL] [Abstract][Full Text] [Related]
53. Biological evaluation of integrin α
Lambidis E; Chen CC; Lumen D; Sánchez AIF; Sarparanta M; Cheng RH; Airaksinen AJ
Eur J Pharm Sci; 2023 Jan; 180():106336. PubMed ID: 36403717
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of prognostic integrin α2β1 PET tracer and concurrent targeting delivery using focused ultrasound for brain glioma detection.
Chung YH; Hsu PH; Huang CW; Hsieh WC; Huang FT; Chang WC; Chiu H; Hsu ST; Yen TC
Mol Pharm; 2014 Nov; 11(11):3904-14. PubMed ID: 25153169
[TBL] [Abstract][Full Text] [Related]
55. The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin.
Schlesinger M; Roblek M; Ortmann K; Naggi A; Torri G; Borsig L; Bendas G
Thromb Res; 2014 May; 133(5):855-62. PubMed ID: 24636486
[TBL] [Abstract][Full Text] [Related]
56. [
Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
[TBL] [Abstract][Full Text] [Related]
57. 64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression.
Cheng Z; Xiong Z; Subbarayan M; Chen X; Gambhir SS
Bioconjug Chem; 2007; 18(3):765-72. PubMed ID: 17348700
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of a
Edem PE; Jørgensen JT; Nørregaard K; Rossin R; Yazdani A; Valliant JF; Robillard M; Herth MM; Kjaer A
Molecules; 2020 Jan; 25(3):. PubMed ID: 31979070
[TBL] [Abstract][Full Text] [Related]
59. Matrix metalloproteinase 9 targeting peptides: syntheses, 68Ga-labeling, and preliminary evaluation in a rat melanoma xenograft model.
Ujula T; Huttunen M; Luoto P; Peräkylä H; Simpura I; Wilson I; Bergman M; Roivainen A
Bioconjug Chem; 2010 Sep; 21(9):1612-21. PubMed ID: 20795647
[TBL] [Abstract][Full Text] [Related]
60. Comparative studies of three 68Ga-labeled [Des-Arg10]kallidin derivatives for imaging bradykinin B1 receptor expression with PET.
Lin KS; Amouroux G; Pan J; Zhang Z; Jenni S; Lau J; Liu Z; Hundal-Jabal N; Colpo N; Bénard F
J Nucl Med; 2015 Apr; 56(4):622-7. PubMed ID: 25745086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]